Feijge M A, van Pampus E C, Lacabaratz-Porret C, Hamulyàk K, Levy-Toledano S, Enouf J, Heemskerk J W
Department of Human Biology/Biochemistry, University of Maastricht, The Netherlands.
Br J Haematol. 1998 Aug;102(3):850-9. doi: 10.1046/j.1365-2141.1998.00844.x.
Increased Ca2+ signal generation may lead to hyperactivity of platelets and contribute to thrombotic complications. Using fura-2-loaded platelets from 51 healthy volunteers, high variability was detected in the Ca2+ responses evoked by the receptor agonists, thrombin and collagen, and the inhibitor of sarco/endoplasmic reticulum Ca2+-ATPases (SERCA), thapsigargin (Tg). Oral intake of 500mg aspirin reduced the magnitude of the Ca2+ responses, and lowered the intra-individual coefficients of variance of the responses by 50%. However, the corresponding inter-individual variance coefficients were only a little influenced by aspirin intake, pointing to subject-dependent factors in Ca2+ handling that are unrelated to thromboxane formation. With each agonist, 6-9% of the subjects had platelets with relatively high Ca2+ responses (> mean + SD) both before and after aspirin intake. In 90% (9/10) of these cases the high responsiveness was confirmed in platelets obtained 6-12 months later. The Tg- but not thrombin-induced Ca2+ responses correlated inversely with the expression levels of SERCA PL/IM 430 (SERCA-3b) in platelets. After aspirin intake, the Ca2+ responses with collagen but not thrombin correlated inversely with SERCA-2b expression. These results suggest that, in the absence of potentiating effects of thromboxane, (i) the amount of PL/IM 430-recognizable SERCA may control the Ca2+ signal when SERCA-2b is specifically inhibited (with Tg), and (ii) the expression of SERCA-2b determine the collagen- but not the thrombin-evoked Ca2+ signal. Accordingly, limited Ca2+-pumping activity by low expression of one of the SERCA isoforms is likely to be one of the factors resulting in increased platelet activity towards collagen or thapsigargin but not thrombin.
钙离子信号生成增加可能导致血小板活性过高,并引发血栓形成并发症。使用来自51名健康志愿者的负载fura-2的血小板,发现受体激动剂凝血酶和胶原蛋白以及肌浆网/内质网钙离子-ATP酶(SERCA)抑制剂毒胡萝卜素(Tg)诱发的钙离子反应具有高度变异性。口服500毫克阿司匹林可降低钙离子反应的幅度,并使反应的个体内变异系数降低50%。然而,相应的个体间变异系数仅受到阿司匹林摄入的轻微影响,这表明钙离子处理过程中存在与血栓素形成无关的个体依赖性因素。对于每种激动剂,6-9%的受试者在服用阿司匹林前后血小板的钙离子反应相对较高(>平均值+标准差)。在90%(9/10)的此类病例中,6-12个月后获得的血小板中证实了高反应性。Tg诱导而非凝血酶诱导的钙离子反应与血小板中SERCA PL/IM 430(SERCA-3b)的表达水平呈负相关。服用阿司匹林后,胶原蛋白诱导的钙离子反应而非凝血酶诱导的钙离子反应与SERCA-2b表达呈负相关。这些结果表明,在没有血栓素增强作用的情况下,(i)当SERCA-2b被特异性抑制(使用Tg)时,PL/IM 430可识别的SERCA量可能控制钙离子信号,(ii)SERCA-2b的表达决定胶原蛋白而非凝血酶诱发的钙离子信号。因此,一种SERCA同工型低表达导致的有限钙离子泵活性可能是导致血小板对胶原蛋白或毒胡萝卜素而非凝血酶活性增加的因素之一。